Compass Therapeutics, Inc. Ratios

Ratios Mar2019 Dec2019 Mar2020 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin 1,099.36%2,821.91%696.97%3,245.37%22,211.08%-6,661.76%
EBIT Margin 999.36%2,772.96%596.97%3,063.00%22,130.27%-6,661.76%
EBITDA Margin 999.36%2,772.96%596.97%3,063.00%22,211.08%-5,788.47%
Operating Margin 999.36%2,772.96%596.97%3,063.00%22,130.27%-6,661.76%
Net Margin 1,099.36%2,829.32%696.97%3,248.90%22,211.08%-6,661.76%
FCF Margin 999.36%2,622.72%596.99%2,963.55%5,738.92%-5,282.24%
Efficiency
Assets Average 148.64M
Equity Average 136.89M
Invested Capital 148.54M125.23M
Asset Utilization Ratio 0.01
Leverage & Solvency
Interest Coverage Ratio -9.99-27.73-5.97-30.63-221.30
Equity Ratio 0.950.89
Times Interest Earned -9.99-27.73-5.97-30.63-221.30
Valuation
Enterprise Value 310.76M634.74M46.42M72.21M
Market Capitalization 310.76M634.74M198.88M199.50M
Return Ratios
Return on Sales 10.99%28.29%6.97%32.49%222.11%-66.62%
Return on Capital Employed -0.41%
Return on Assets -0.38%
Return on Equity -0.41%